Table 1.

Characteristics of included studies

Author	Year	Location	Hematuria cohort	Biomarker	Biomarker Cut-off	Age [range]	Cancers diagnosed on the reference test	Positive’ Biomarker test	All cancers diagnosed on biomarkers	TP	FN	FP	TN
Akagashi	2001	Japan	121	NMP22 (quantitative)	9.2	NR	12	52	11	11	1	41	73
Arora	2009	India	53	NMP22 (qualitative)	NA	59 [range 33–83]	38	33	30	30	8	3	12
Cha	2012	Germany/Italy	1182	uCyt	NA	65 [range 18–93]	245	328	202	202	43	126	811
Chong	1999	Singapore	47	BTA (qualitative)	NA	NR	12	20	8	8	4	12	23
Gonzalo Rodriguez	2008	Spain	15	NMP22 (qualitative)	10	59.8 [range 27–85]	12	10	10	10	2	0	3
Kirollos	1997	UK	24	BTA (qualitative)	NA	NR	1	7	1	1	0	6	17
Lotan	2008	International	1166	NMP22 (qualitative)	NA	59 [range 18–96]	74	203	43	43	52	160	932
Miyanaga	1999	Japan	309	NMP22 (quantitative)	12	NR	22	88	20	20	2	68	221
Moonen	2005	Netherlands	28	NMP22 (qualitative)	NR	NR	4	6	4	4	0	2	22
Oge	2001	Turkey	37	NMP22 (quantitative)	10	NR	27	24	20	20	7	4	6
O’Sullivan	2012	Australasia	485	CxBladder	69 [IQR 59–77]	66	116	33	54	12	62	354
Sanchez-Carbayo	2001	Spain	112	NMP22 (quantitative)	10	65.5 [range 23 to 87]	43	35	28	28	19	7	45
Sarosdy	2006	United States	497	UroVysion	NR	63 [range 40–97]	51	124	35	35	16	89	333
Schmitz-Drager	2008	Germany	293	uCyt	NA	59 [range 24–89]	27	53	22	23	4	32	221
van Kessel	2016	Netherlands	154	AssureMDx	0.1917196	68 [range 38–91]	74	85	72	72	2	13	67
van Kessel	2017	Netherlands	200	AssureMDx	0.1917196	NR	97	105	90	90	7	15	88
Zippe	1999	USA	180	NMP22 (quantitative)	10	NR	18	63	18	18	0	32	130